Substance / Medication

Anagrelide

SNOMED 372561005 UMLS C0051809

Overview

Active Ingredient

anagrelide

RxNorm CUI

596724

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Thrombocytosis

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

1 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients

NCT00202644Phase 4Completed150 enrolled

View all 1 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Anagrelide in the management of essential thrombocythemia: a systemic review and meta-analysis.

Abreu Lopez Barbara, Arvelaez Pascucci Joanne, Ramzy Safiya Mohamed et al. · Int J Hematol · 2025

PMID: 40057935Meta-Analysis

Pharmacokinetics of a Novel Anagrelide Extended-Release Formulation in Healthy Subjects: Food Intake and Comparison With a Reference Product.

Petrides Petro E, Schoergenhofer Christian, Widmann Rudolf et al. · Clin Pharmacol Drug Dev · 2018

PMID: 28301098RCTFull text (PMC)

Pharmacokinetics, bioequivalence, tolerability, and effects on platelet counts of two formulations of anagrelide in healthy volunteers and patients with thrombocythemia associated with chronic myeloproliferation.

Petrides Petro E, Gisslinger Heinz, Steurer Michael et al. · Clin Ther · 2009

PMID: 19302911RCT

Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25 years by the "Ph1-negative Myeloproliferative Neoplasms Latium Group".

Mazzucconi Maria Gabriella, Baldacci Ermina, Latagliata Roberto et al. · Eur J Haematol · 2020

PMID: 32441419Observational

Comparison of starting doses of anagrelide as a first-line therapy in patients with cytoreductive therapy-naïve essential thrombocythemia: difference between starting at 0.5 and 1.0 mg/day.

Hashimoto Yoshinori, Ito Tomoki, Tanaka Yasuhiro et al. · Int J Hematol · 2020

PMID: 32328973Observational

Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide.

Tefferi Ayalew, Szuber Natasha, Vallapureddy Rangit R et al. · Am J Hematol · 2019

PMID: 30252953Observational

Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study.

Cascavilla Nicola, De Stefano Valerio, Pane Fabrizio et al. · Drug Des Devel Ther · 2015

PMID: 26028965ObservationalFull text (PMC)

Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis.

Samuelson Bethany, Chai-Adisaksopha Chatree, Garcia David · J Thromb Thrombolysis · 2015

PMID: 25894476Observational

[Efficacy and safety of anagrelide in treatment of essential thrombocythemia: multicenter, randomized controlled clinical trial].

Ge Xiaoyan, Yang Linhua, Jin Jie et al. · Zhonghua Xue Ye Xue Za Zhi · 2015

PMID: 26304075ObservationalFull text (PMC)

Anagrelide treatment and cardiovascular monitoring in essential thrombocythemia. A prospective observational study.

Tortorella Giovanni, Piccin Andrea, Tieghi Alessia et al. · Leuk Res · 2015

PMID: 25850727Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Anagrelide (substance)
SNOMED CT: 372561005
UMLS CUI: C0051809
RxNorm CUI: 596724

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.